Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression
T. Masu, M. Atsukawa, K. Nakatsuka, M. Shimizu, D. Miura, T. Arai, H. Harimoto, C. Kondo, K. Kaneko, S. Futagami, C. Kawamoto, H. Takahashi, K. Iwakiri
This study shows that combining anti-CD137 mAb with trastuzumab enhances NK cell-mediated ADCC against HER2-low pancreatic cancer cells, particularly in individuals with FcγRIIIA-VV/VF genotype.
bioRxiv · Jul 3, 2018Immunology